These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 33563773)

  • 41. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
    BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
    Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR
    J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
    J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
    J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.
    Juloori A; Katipally RR; Lemons JM; Singh AK; Iyer R; Robbins JR; George B; Hall WA; Pitroda SP; Arif F; Fung J; Pillai A; Liao CY; Sharma M; Liauw SL
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):202-213. PubMed ID: 36108891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
    Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
    Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
    Kaseb AO; Hasanov E; Cao HST; Xiao L; Vauthey JN; Lee SS; Yavuz BG; Mohamed YI; Qayyum A; Jindal S; Duan F; Basu S; Yadav SS; Nicholas C; Sun JJ; Singh Raghav KP; Rashid A; Carter K; Chun YS; Tzeng CD; Sakamuri D; Xu L; Sun R; Cristini V; Beretta L; Yao JC; Wolff RA; Allison JP; Sharma P
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):208-218. PubMed ID: 35065057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.
    Scheiner B; Kirstein MM; Hucke F; Finkelmeier F; Schulze K; von Felden J; Koch S; Schwabl P; Hinrichs JB; Waneck F; Waidmann O; Reiberger T; Müller C; Sieghart W; Trauner M; Weinmann A; Wege H; Trojan J; Peck-Radosavljevic M; Vogel A; Pinter M
    Aliment Pharmacol Ther; 2019 May; 49(10):1323-1333. PubMed ID: 30980420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer.
    Kaneko A; Kobayashi N; Miura K; Matsumoto H; Somekawa K; Hirose T; Kajita Y; Tanaka A; Teranishi S; Sairenji Y; Kawashima H; Yumoto K; Tsukahara T; Fukuda N; Nishihira R; Watanabe K; Horita N; Hara Y; Kudo M; Miyazawa N; Kaneko T
    Thorac Cancer; 2024 May; 15(15):1208-1217. PubMed ID: 38602166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
    Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
    Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
    Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
    Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.
    Kasi PM; Budde G; Krainock M; Aushev VN; Koyen Malashevich A; Malhotra M; Olshan P; Billings PR; Aleshin A
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.